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Currently, there is no effective long‐term treatment for intervertebral disc (IVD)
degeneration, making it an attractive candidate for regenerative therapies. Hydrogel
delivery of adipose stem cells (ASCs) in combination with controlled release of bioac-
tive molecules is a promising approach to halt IVD degeneration and promote regen-
eration. Growth differentiation factor 6 (GDF6) can induce ASC differentiation into
anabolic nucleus pulposus (NP) cells and hence holds promise for IVD regeneration.
Here, we optimised design of novel poly(DL‐lactic acid‐co‐glycolic acid) (PLGA)–poly-
ethylene glycol–PLGA microparticles to control GDF6 delivery and investigated
effect of released GDF6 on human ASCs differentiation to NP cells. Recombinant
human (rh)GDF6 was loaded into microparticles and total protein and rhGDF6 release
assessed. The effect of microparticle loading density on distribution and gel formation
was investigated through scanning electron microscopy. ASC differentiation to NP
cells was examined after 14 days in hydrogel culture by quantitative polymerase chain
reaction, histological, and immunohistochemical staining in normoxic and IVD‐like
hypoxic conditions. RhGDF6 microparticles were distributed throughout gels without
disrupting gelation and controlled rhGDF6 release over 14 days. Released GDF6 sig-
nificantly induced NP differentiation of ASCs, with expression comparable with or
exceeding media supplemented rhGDF6. Microparticle‐delivered rhGDF6 also up‐
regulated sulphated glycosaminoglycan and aggrecan secretion in comparison with
controls. In hypoxia, microparticle‐delivered rhGDF6 continued to effectively induce
NP gene expression and aggrecan production. This study demonstrates the effective
encapsulation and controlled delivery of rhGDF6, which maintained its activity and
induced ASC differentiation to NP cells and synthesis of an NP‐like matrix suggesting
suitability of microparticles for controlled growth factor release in regenerative strat-
egies for treatment of IVD degeneration.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Cell‐mediated regenerative therapy, in combination with delivery of
small bioactive molecules, is an attractive strategy for the treatment
of intervertebral disc (IVD) degeneration, a leading cause of low back
pain (Balagué, Mannion, Pellisé, & Cedraschi, 2012; Cheung et al.,
2009). Low back pain affects approximately 84% of the global popula-
tion, resulting in a significant socio‐economic burden surpassing many
other causes of disability, including arthritis (Juniper, Le, & Mladsi,
2009; Maniadakis & Gray, 2000; Martin et al., 2008; Risbud & Shapiro,
2014). Although current conservative treatments offer relief from pain
and improved functionality in the short term, progressive degenera-
tion can make surgery necessary. However, surgical intervention often
results in adjusted spinal loading, and in turn, degeneration of IVDs
adjacent to intervention sites (Atlas, Keller, Wu, Deyo, & Singer,
2005). Hence, novel approaches to regenerate tissue and restore func-
tion are required.
IVD degeneration arises from cell‐mediated changes in the extracel-
lular matrix (ECM) of the central portion of the disc, the nucleus
pulposus (NP). Inflammatory positive feedback‐directed mechanisms
progressively degrade the healthy Type 2 collagen and aggrecan‐rich
matrix, replacing it withType 1 collagen. This reduces osmotic pressure
in the NP, altering load bearing and resulting in mechanical failure of the
annulus fibrosus (AF; a fibrous collagenous tissue circumferentially
enclosing the NP). Progressive injury, including tearing and fissure for-
mation, to the AF and NP from increased localised compressive stress
creates a proinflammatory environment, inflaming surrounding tissues
and further increasing the expression of catabolic enzymes and factors
(Johnson, Schoepflin, Choi, Shapiro, & Risbud, 2015; Risbud & Shapiro,
2014). This process is concomitant with in‐growth of blood vessels and
nociceptive nerve fibres into the IVD, facilitating immune cell infiltration
and thought to increase pain (Freemont et al., 1997; Hughes, Freemont,
Hukins, McGregor, & Roberts, 2012).
Therapeutic regeneration strategies aim to abrogate this proinflam-
matory, catabolic positive feedback loop through the implantation of
healthy cells and/or signalling molecules to instruct correct ECM pro-
duction, particularly in the NP. One growth factor recently proposed
forNP regeneration is growth differentiation factor 6 (GDF6), amember
of the bone morphogenetic protein (BMP) family that plays important
developmental roles in the formation of cartilaginous tissues, including
the IVD (Clendenning & Mortlock, 2012; Settle et al., 2003; Tassabehji
et al., 2008; Wei et al., 2016). GDF6 expression has been linked to
anti‐ageing effects in multiple tissues (Hisamatsu, Ohno‐Oishi,
Nakamura, Mabuchi, & Naka‐Kaneda, 2016) and, whereas studies con-
ducted in our laboratory and others do not suggest GDF6 expression
decreases with degeneration (Gulati, Chung, Wei, & Diwan, 2015; Le
Maitre, Freemont, & Hoyland, 2009), preclinical studies havedemonstrated that injection of GDF6 into experimentally induced rab-
bit and ovine annular puncture models attenuates pro‐inflammatory
molecular changes and prevents progression of IVD degeneration
(Miyazaki et al., 2018; Shen et al., 2009). However, the hypocellular
nature of the tissue and the aberrant phenotype of degenerate NP cells
suggests that growth factor therapy alone may be insufficient to pro-
mote regeneration of human IVD. We believe a therapy which com-
bines cells and an appropriate signalling molecule, such as GDF6, may
offer benefits over monotherapy approaches.
Due to difficulties in extracting and expanding autologous or allo-
geneic NP cells, multipotent adult stem cells, such as those derived
from bone marrow or adipose tissue, have emerged as promising cell
sources (Risbud et al., 2004; Rodrigues‐Pinto et al., 2016; Sakaguchi,
Sekiya, Yagishita, & Muneta, 2005; Strassburg, Richardson, Freemont,
& Hoyland, 2010). Recently, we demonstrated the in vitro differentia-
tion of bone marrow‐derived mesenchymal stem cells (MSCs) and adi-
pose stem cells (ASCs) into an NP phenotype through stimulation with
a total of 700 ng recombinant human GDF6 (rhGDF6) delivered exog-
enously as a media supplement over a 14‐day timecourse (Clarke
et al., 2014). Furthermore, stimulation with rhGDF6 produced an NP,
rather than a chondrocytic phenotype, more efficiently than other fac-
tors commonly used for chondrogenic and NP differentiation of MSCs
in vitro, specifically TGFβ3 and GDF5. This was evidenced by expres-
sion of defined NP‐specific marker genes, total sulphated glycosami-
noglycan (sGAG) production, and importantly increased aggrecan to
collagen Type 2 ratio, which constitutes an important difference
between NP and articular cartilage ECM (Mwale, Roughley, &
Antoniou, 2004). Significantly, ASCs were observed to adopt an NP
phenotype significantly more efficiently than MSCs.
However, in order to translate a combined ASC–rhGDF6 therapy
to clinic, a delivery system that controls the release of GDF6,
prolonging its presence in the IVD, protecting it from rapid enzymatic
degradation and lowering required effective doses is a desirable tar-
get. This is especially pertinent in IVD regeneration, where repeated
injection may trigger further degeneration (Han et al., 2008; Hsieh,
Hwang, Ryan, Freeman, & Kim, 2009; Zhang, La Marca, Hollister,
Goldstein, & Lin, 2009). Control of growth factor delivery can be
achieved by incorporating the growth factor into a biomaterial carrier
system to provide protection from proteolytic enzymes and prevent
growth factor degradation (Vo, Kasper, & Mikos, 2012). Spatio‐
temporal control of growth factor delivery has been achieved via
encapsulation within polymeric microparticles (MPs), whereby regula-
tion of release duration has been achieved alongside limiting growth
factor dose (Chen, Silva, Yuen, & Mooney, 2007; G. T. S. Kirby et al.,
2011; Sands & Mooney, 2007). Homo and copolymers of lactide and
glycolide have found particular application as delivery vehicles as they
are FDA‐approved for various clinical functions (Middleton & Tipton,
HODGKINSON ET AL. 32000), degrade in vivo into natural products (lactic and glycolic acid)
that are processed by normal metabolic pathways (Göpferich, 1996;
Lu et al., 2000), and have tuneable physico‐chemical properties (Vo
et al., 2012). Controlled release from MPs formed from polymers such
as poly(DL‐lactic acid‐co‐glycolic acid) (PLGA) is typically dependent
upon the degradation rate, which in turn can be altered by changing
the lactide: glycolide ratio or molecular weight (Keles, Naylor, Clegg,
& Sammon, 2015). Previously, we have developed improved methods
for growth factor delivery by decoupling release kinetics from polymer
degradation by the inclusion of a more hydrophilic component, such as
polyethylene glycol (PEG; White et al., 2013). The addition of an “in‐
house” developed triblock copolymer, PLGA–PEG–PLGA provides
additional control over polymer hydration to achieve sustained deliv-
ery (G. Kirby et al., 2016; White et al., 2013)
Therefore, the aim of this study was to encapsulate rhGDF6 in
novel PLGA/PLGA–PEG–PLGA MPs to control its release over a
defined timescale in vitro. Polymer MP delivery was investigated as
this system offers high growth factor entrapment efficiency, the dry
MPs have a long storage life, and MPs can be easily incorporated into
injectable load‐bearing hydrogel systems without significant detriment
to mechanical properties [37]. The biological effects of the released
rhGDF6 on the differentiation of primary human ASCs in 3D culture
were assessed and compared with rhGDF6 delivered exogenously as
a media supplement.TABLE 1 Triblock copolymer characteristics
MN
a
% mole
lactidea
% mole
glycolidea MN
b MW
b PDIb
1600–1500–1600 75 25 3026 4582 1.51
aDetermined by 1H nuclear magnetic resonance.
bDetermined by gel permeation chromatography (GPC).2 | METHODS
2.1 | Triblock copolymer fabrication and
characterisation
The triblock copolymer PLGA–PEG–PLGA was prepared in‐house and
analysed using previously described methods (White et al., 2013).
Briefly, synthesis occurred by ring‐opening polymerisation of the DL‐
lactide and glycolide monomers in the presence of PEG and the Sn
(Oct)2 catalyst under a dry nitrogen atmosphere, as reported (Hou
et al., 2008; Zentner et al., 2001). The reaction was allowed to proceed
for 8 hr and the resultant copolymer was dissolved and precipitated in
water to remove unreacted monomers. The triblock copolymer was
then dried under vacuum and stored at −20°C until required.
Characterisation of the triblock copolymer was undertaken as pre-
viously described (White et al., 2013). Nuclear magnetic resonance
analysis of the copolymer was undertaken using a Bruker DPX‐300
Spectrometer (300 MHz) with deuterated choloroform (CDCl3) as
the solvent. A tetramethylsilane signal was taken as the zero chemical
shift. The composition of the copolymer was determined by 1H
nuclear magnetic resonance by integrating the signals pertaining to
each monomer, that is, peaks from CH2 of ethylene glycol and
glycolide and CH and CH3 from DL‐lactide (Hou et al., 2008). The
molecular weight and polydispersity index of the copolymer was
determined using gel permeation chromatography (PL‐GPC 120, Poly-
mer Labs) with differential refractometer detection. Tetrahydrofuran
was employed as an eluent, with two columns (30 cm, PolarGel‐M)in series calibrated against polystyrene standards. Characteristics of
the triblock copolymer are presented in Table 1.2.2 | MP fabrication
MPs were prepared according to a previously described method
involving a water/oil/water double‐emulsion solvent evaporation
technique (G. T. S. Kirby et al., 2011; White et al., 2013). PLGA poly-
mer with a lactide: glycolide ratio of 85:15 (PLGA 85:15 DLG 4CA
LP421 53 kDa) was purchased from Surmodics (Eden Prairie, MN
USA). Briefly, 0.7 g PLGA and 0.3 g triblock (PLGA–PEG–PLGA), that
is, 1 g in total, was dissolved in dichloromethane (5 mL) to form the
oil phase. A protein mixture consisting of 1 mg rhGDF6 and 9 mg
human serum albumin (HSA; for rhGDF6‐MPs), or 10 mg HSA (for
control‐MPs) was dissolved in deionised water (100 μL). The aqueous
solution was added to the oil phase and homogenised using an LM5
axial impeller mixer (Silverson machines, Ltd, Chesham, UK) for 2 min
at 4,000 rpm. This primary water/oil emulsion was quickly added to
a 200 mL bath of polyvinyl alcohol (PVA) (0.3%) and homogenised
again for 2 min at 9,000 rpm. This water/oil/water emulsion was
stirred at 300 rpm on a Variomag 15‐way magnetic stirrer for 4 hr
to facilitate DCM evaporation. MPs were then filtered, washed and
lyophilized (Edwards Modulyo, IMA Edwards, UK) until dry. Control
(blank) MPs were manufactured without protein, using 100 μl distilled
water in the primary emulsion. Blank MPs of two different size ranges
were fabricated for use in collagen gel experiments: <50 μm, denoted
“small” and ~100 μm, denoted “large.” Small MPs were prepared as
described above. For large particles, the aqueous solution was added
to the oil phase as described above, that is, homogenised at
4,000 rpm for 2 min and the water/oil emulsion was then added to
the PVA bath and homogensised for 2 min at 2000 rpm.2.3 | MP characterisation
MPs (50 mg/ml in double deionised water) were sized using a laser dif-
fraction method (Coulter LS230, Beckman Coulter, UK) with agitation
to prevent particles settling. To assess the morphology of the MPs,
thin layers of freeze‐dried MPs were adhered to an adhesive stub
and gold sputter coated for 4 min at 30 mA (Balzers SCD 030 gold
sputter coater, Balzers, Liechenstein). MPs were imaged using a JSM
6060LV scanning electron microscope (SEM; JEOL, Welwyn Garden
City, UK) with the accelerating voltage set to 10 kV.
4 HODGKINSON ET AL.2.4 | Quantification of GDF6 release from PLGA
MPs
To quantify the controlled release of total protein and GDF6 fromMPs
in culture conditions, micro‐bicinchoninic acid assay (BCA) assays
(Pierce) and GDF6 enzyme‐linked immunosorbent assay (ELISA) assays
(Life Span Biosystems) were utilised, respectively. Aliquots (25 mg) of
the MPs (triplicate samples from each batch) were suspended in
1.5 ml phosphate‐buffered saline (PBS, pH 7.4); samples were gently
rocked on a 3D shaker (Gyrotwister, Fisher Scientific UK Ltd) at 5 rpm
in a humidified incubator at 37°C. At defined time intervals, the PBS
was removed from theMPs and replacedwith 1.5ml fresh PBS; all liquid
above the particles was collected without removing particles. The
removed supernatants were stored frozen until required and were then
assayed for total protein content using the micro‐BCA assay kit with a
standard curve of HSA (0–40 μg/ml). For analysis of GDF6 release,
sandwich ELISA assays were conducted according to manufacturer's
recommendations (Life Span Biosystems) and GDF6 concentrations
determined by comparison with defined GDF6 standards.2.5 | ASC isolation and culture
Subcutaneous adipose tissue was obtained from patients undergoing
hip‐replacement surgery with full written informed consent, and all
procedures and experiments were performed with relevant Research
Ethics Committee and The University of Manchester approvals. ASCs
were isolated as previously described (Burrow, Hoyland, & Richardson,
2017; Clarke et al., 2014). Briefly, adipose tissue was dissected from
non‐adipose tissue, minced into small pieces and incubated at 37°C
in 15 ml Hanks balanced salt solution containing 0.2% (w/v) Type 1
collagenase and 20 mM calcium chloride for 2 hr with gentle agitation
to allow digestion of the tissue. The digested solution was filtered
through a 70‐μm cell strainer, neutralised with MSC expansion
medium (αMEM (Sigma‐Aldrich) containing 110 mg L−1 sodium pyru-
vate, 1000 mg L−1 glucose, 100 U ml−1 penicillin, 100 μg ml−1 strepto-
mycin and 0.25 μg ml−1 amphotericin, 2 mM GlutaMAX (Life
Technologies) and 10% (v/v) FBS) and centrifuged for 5 min. Finally,
the supernatant was aspirated, cells resuspended in MSC expansion
medium, and adherent cells cultured to confluence. Cells were incu-
bated at 37°C with 5% CO2 and 20% O2 unless otherwise stated.
The CD profile of ASCs was analysed through flow cytometry and
multipotency assessed along the three mesenchymal lineages by using
standard methods (data not shown; Burrow et al., 2017). Cells at Pas-
sage 3 or below were used for subsequent experiments.2.6 | 3D collagen gel cultures with and without MPs
Type 1 collagen hydrogels were prepared to a final cell density of
4 × 106 ml−1 (Clarke et al., 2014) by resuspending an appropriate num-
ber of pelleted ASCs in one‐part complete media prior to the addition
of the eight‐parts atelosoluble Type 1 collagen (Devro, pH 2, 3 mg ml
−1). The solution was then neutralised to pH 7 with one‐part phosphatebuffer (0.2 M sodium phosphate, 1.3 M sodium chloride, pH 11), briefly
mixed by pipetting to distribute the cells evenly and a volume of 100 μl
was transferred into high density translucent membrane cell culture
inserts (pore size 0.4 μm, BD Biosciences). If gels were to contain
MPs, these were added at the correct concentration to the one‐part
complete media and mixed with the collagen to disperse them within
the gel. The culture inserts were maintained with 750 μl media within
the well of the plate and the plates transferred to the incubator at
37°C for 1 hr before 500 μl media was pipetted on top of the hydrogel
itself to ensure adequate diffusion of nutrients. After 24 hr, culture
medium was replaced with differentiating media consisting of high‐
glucose Dulbecco's Modified Eagles Medium (DMEM), 1% FCS,
insulin‐transferring‐selenium (ITS‐X; Gibco, NY, USA), 100 μM ascorbic
acid‐2‐phosphate, 1.25 mg ml−1 bovine serum albumin, 10−7 M dexa-
methasone, 5.4 μg ml−1 linoleic acid, 40 μg ml−1 L‐proline,100 U ml−1
penicillin, 100 μg ml−1 streptomycin, 2.5 μg ml−1 amphotericin B, and
if designated, 100 ng ml−1 GDF 6. Media was changed every 48 hr,
which included 100 ng ml−1 rhGDF6 in culture groups receiving exoge-
nous rhGDF6 supplementation.2.7 | Hypoxic gel culture
To study the effect of hypoxia on MP‐released GDF6‐induced NP
marker gene expression, ASCs were set up in 3D collagen gel culture
a described above with either GDF6‐MPs or control‐MPs in hypoxic
(5% O2) and normoxic culture conditions for 14 days. Media was
changed every other day. After 14 days, RNA was extracted for gene
expression analysis and immunohistochemistry staining performed.2.8 | Scanning electron microscopy
Acellular collagen gels were prepared as above with determined con-
centrations of MPs. Gels were mixed and allowed to gel at 37°C for
1 hr. Gels were subsequently submerged in media incubated at 37°C
overnight. For analysis, gels were removed from well inserts, fixed in
3% gluataraldehyde, dehydrated through an ethanol gradient, and crit-
ical point dried. For cross‐sectional analysis, dry constructs were then
dissected vertically through the midline and the exposed faces imaged
through SEM.2.9 | Smad1 phosphorylation ELISA
Cells were seeded into wells at a density of 5 × 104 cells per cm2 and
serum starved for 24 hr. Cells were then washed with PBS and incu-
bated in serum‐free MSC expansion media with and without rhGDF6.
RhGDF6 from MPs was obtained through prior incubation in sterile
PBS to release MP contents. This was quantified through GDF6 ELISA
(as above). RhGDF6‐MP and exogenous rhGDF6 were added to rele-
vant test cultures at 100 ng ml−1 and cells incubated with or without
rhGDF6 for 1 hr at 37°C. After incubation, cells were washed three
times with ice‐cold PBS and protein extracted with cell lysis buffer
(provided with ELISA assay) supplemented with protease and
HODGKINSON ET AL. 5phosphatase inhibitors (Life Technologies). Protein was quantified
through BCA assay (Pierce) and normalised per well. Phospho‐smad1
ELISA assays (RayBiotech) were performed according to manufac-
turer's instructions and smad1 phosphorylation quantified through
measuring absorbance at 450 nm.2.10 | Quantitative real‐time PCR
For RNA extraction, cells were disrupted inTRI Reagent (Sigma–Aldrich)
and RNA isolated, quantified through ultraviolet spectroscopy
(NanoDrop, Thermo Scientific) and cDNA synthesized as previously
described (Burrow et al., 2017). To analyse the gene expression profiles
of different cDNA samples, quantitative polymerase chain reaction
(qPCR) reactions were undertaken using the TaqMan qPCR system.
FAM‐BHQ1 probes were utilised at a concentration of 450 mM and
optimal primer concentration determined empirically (Table 2). QPCR
reactions were run on an Applied Biosystems StepOne Plus Real Time
PCR System. The reaction master mix contained 5 μl 2X Lumino Ct
qPCR Readymix, 1 μl forward primer, 1 μl reverse primer, and 0.5 μl
probe and 0.5 μl 40X ROX internal reference dye. Mastermix was
vortexed and 8 μl pipetted into each well of the 96‐well plate. Biological
samples were examined in triplicate and 2 μl of cDNA (5 ng/μl) was
pipetted into each well. A positive and negative sample was run for each
gene examined to ensure no false positives; total human RNA and
molecular grade H2O replaced cDNA, respectively. The reactions were
cycled under the following conditions: 95°C for 20 s followed by
40 cycles of 95°C for 1 s and 60°C for 20 s. Data was analysed accord-
ing to the 2‐ΔCt method outlined by Livak and Schmittgen (Livak &
Schmittgen, 2001) and normalised to two internal prevalidated refer-
ence genes MRPL19 and GAPDH.2.11 | Histological characterisation of ECM
deposition
Collagen constructs were embedded in optimal cutting temperature
(OCT), snap frozen in liquid nitrogen, and cryosectioned into 6‐μmTABLE 2 Quantitative polymerase chain reaction primer and probe sequ
Gene Forward primer Reverse prim
SOX9 GCTCTGGAGACTTCTGAA GGTACTTG
COL2A1 GGCTTCCATTTCAGCTATG CAGTGGTA
ACAN GGCTTCCACCAGTGTGAC GTGTCTCG
KRT8 CCTCATCAAGAAGGATGTG CCTGAGGA
KRT18 CTGCTGAACATCAAGGTC AGGCATCA
KRT19 CCATGAGGAGGAAATCAGTA GTCACTCA
FOXF1 CCGTATCTGCACCAGAAC TGGCGTTG
GAPDH CTCCTCTGACTTCAACAG CGTTGTCA
MRPL19 CCACATTCCAGAGTTCTA CCGAGGAT
Note. Primers were added per reaction at 900 nM with 250 nM probe.sections. Aggrecan production was investigated through immunohis-
tochemical analysis (IHC) of gels. Briefly, gels were embedded into
OCT and frozen on dry ice. Gels were cut into 8‐μm thick cross‐
sections and collected onto SuperFrost Plus slides. For IHC, sections
were allowed to equilibrate to room temperature, formalin fixed and
blocked prior to addition of aggrecan primary antibodies (Burrow
et al., 2017), and incubated at 4°C overnight. The relevant HRP‐
conjugated secondary antibody was added after washing (5 × 5 min
TBS with 0.1% (v/v) Tween 20; TBST) and incubated at room tem-
perature for 1 hr. Following washing with TBST, specific staining
was visualised through incubation at room temperature with 3,3'‐
diaminobenzidine (DAB) Chromagen. Bright field images were
acquired from three independent gel cultures and representative
images depicted.2.12 | Statistical analysis
Statistical analysis was performed with GraphPad InStat and Prism
software. For qPCR, multiple comparisons and ELISA analysis data
was compared using Kruskal–Wallis with Dunn's multiple comparisons
tests to assess significance differences between treatment groups and
unstimulated controls, with p values <.05 deemed significant. Numer-
ical and graphical results are displayed as mean ± SEM.3 | RESULTS
3.1 | RhGDF6 release was controlled by
encapsulation into MPs in culture conditions
Previous experiments demonstrated effective ASC differentiation to
NP cells in 3D collagen cultures over a 14‐day culture period with a
cumulative total of 700 ng rhGDF6 stimulation (Clarke et al., 2014).
Therefore, MPs were designed to release their contents over this
period. The MPs produced were free‐flowing, with a smooth, spherical
morphology (Figure 1a). Each of the three MP formulations (‘HSA/
rhGDF6’,‘HSA’, or ‘water only control’) had a similar size distribution,ences used in this study
er Probe (FAM‐MGB)
TAATCCGGGTG TCCTTCTTGTGCTGCACGCG
GGTGATGTTC CCAACACTGCCAACGTCCAG
GATGCCATACG TGACCAGACTGTCAGATACCCCATCCA
AGTTGATCTC CTTCCAGGCGAGACTCCAGC
CCAAGATTAAAG CTGAGATCGCCACCTACCGC
GGATCTTGGC AATCCACCTCCACACTGACCTG
AAAGAGAAGA CCGAGCTGCAAGGCATCCCG
TACCAGGAAA CACCCACTCCTCCACCTTTGA
TATAAAGTTCAAA CAAATCTCGACACCTTGTCCTTCG
FIGURE 1 Microparticle (MP) morphology, size distribution, and protein/recombinant human growth differentiation factor 6 (rhGDF6) release in
culture conditions. Size distributions and morphology of particles produced from poly(DL‐lactic acid‐co‐glycolic acid) (PLGA) 85:15 with 30%
PLGA–polyethylene glycol–PLGA. (a) Representative scanning electron microscope image of particles is of microparticles produced with
encapsulated human serum albumin (HSA)/rhGDF6. Size distributions of (b) HSA/rhGDF6‐encapsulated microparticles, (c) HSA only, and (d) water
only control. (e) Total protein release from MPs under culture conditions was assessed over 14 days in culture through bicinchoninic acid assays on
collected supernatant. Data represents means ± standard deviation (n = 3) (f) GDF6 enzyme‐linked immunosorbent assay (ELISA) analysis of rhGDF6
released fromMPs over 14 days in culture conditions. Data representsmeans ± standard deviation (n = 3). Total protein andGDF6 ELISA results show
comparable release profiles indicating controlled release over 14 days in culture [Colour figure can be viewed at wileyonlinelibrary.com]
6 HODGKINSON ET AL.with mean particle sizes of 14–19 μm (Figure 1b–d). Total protein
released, assessed through BCA assay, was controlled over the 14‐
day culture (Figure 1e). However, an initial burst of protein, amounting
to 55% of the total protein released, was released after 24 hr culture.
Subsequently, 90% of the total released protein was released by 7 days
culture, with the remaining 10% released by 15 days in culture. Mean
total released protein was 4.75 μg/mg MP (75% of total loaded pro-
tein). The release profile was confirmed by GDF6‐specific ELISA anal-
ysis of the released protein (Figure 1f). Comparably, 56% of total
delivered GDF6 was released after 1‐day culture, 85.5% by 7 days cul-
ture, and the remaining 14.5% released by 15 days culture. After
15 days, a total 620 ng/mg MP was released (88.6% of total loaded
GDF6).3.2 | MPs could be incorporated into collagen gel 3D
culture
Protein release data demonstrated that 1.13 mg of MPs (11.3 mg ml−1)
were required per gel construct to deliver optimal (700 ng) quantities
of rhGDF6 to induce human ASC differentiation to NP cells. There-
fore, the effects of incorporating therapeutically relevant quantities
of MPs into the collagen gel constructs were analysed. SEM confirmed
effective incorporation and distribution of MPs through collagen gel
constructs, even for concentrations ~20× (200 mg ml−1) that required
for rhGDF6 delivery (Figure 2). Conversely, at therapeutic concentra-
tions (≥10 mg ml−1), larger MPs (~100 μm) aggregated at gel exteriors
and disrupted gel formation. This demonstrated the importance of
FIGURE 2 Loading density of microparticles (MPs) in collagen gels. Scanning electron microscope images of MP‐loaded collagen gels. Small
microparticles (14–19 μm) demonstrated effective incorporation into collagen gels even at high density 20 times that required for effective
recombinant human growth differentiation factor 6 delivery. Large MPs (100 μm) were seen to aggregate at high density and form external layers,
therefore small MPs were selected for downstream experimentation [Colour figure can be viewed at wileyonlinelibrary.com]
HODGKINSON ET AL. 7considering MP size and hence smaller (mean 14‐19 μm) MPs were
taken forward to analyse the activity of released rhGDF6.
3.3 | RhGDF6 released from MPs increased
expression of NP marker genes in ASCs
To assess whether released rhGDF6 was active and able to activate
cellular signalling pathways, phospho‐smad1 ELISA assays were per-
formed. Smad1 phosphorylation was seen to be significantly increased
in comparison with unstimulated cells (Figure 3a; p = .015). Smad1
activation by rhGDF6 released from MPs was comparable with
rhGDF6 supplemented to media (p = .100) at the same concentration
indicating no loss of function through encapsulation.
After 14 days, culture with rhGDF6‐MPs induced the upregula-
tion of conventional and novel NP marker genes in comparison
with unstimulated controls (Figure 3b). Conventional markersSOX9 (p < .0001), COL2A (p = .017), and ACAN (p < .0001) were
significantly upregulated in constructs containing rhGDF6‐MPs
versus unstimulated control constructs after 14 days. Additionally,
there were significant increases in the novel NP marker
genes FOXF1 (p = .013), KRT18 (p = .0002), and KRT19 (p = .027)
in constructs containing rhGDF6‐MPs versus unstimulated
control constructs after 14 days. Control MPs did not promote
increased expression of any of the genes studied, confirming
that differentiation was driven by GDF6 rather than the MPs
themselves.
Crucially, MP delivery of rhGDF6 either matched or increased
gene NP marker gene expression in comparison with exogenous addi-
tion of rhGDF6 to the media, with significant upregulations observed
in SOX9 (p < .0001), COL2A1 (p = .0028), ACAN (p = .0004), FOXF1
(p = .0019), and KRT19 (p = .01) compared with exogenous rhGDF6
addition.
FIGURE 3 Effect of microparticle (MP)–encapsulated recombinant human growth differentiation factor 6 (rhGDF6) on SMAD response and
nucleus pulposus (NP)–marker gene expression in adipose stem cells (ASCs). (a) Smad1 phosphorylation assessed by enzyme‐linked
immunosorbent assay. MP‐encapsulated rhGDF6 remained active on release and was able to induce smad1 phosphorylation in ASCs with a similar
effectiveness to exogenous rhGDF6 added directly to culture media. Data represents means ± standard deviation, normalised to unstimulated
controls (n = 3; # p < .05 rhGDF6 vs. Control; Ψ p < .05 rhGDF6‐MP vs. Control). (b) Quantitative polymerase chain reaction analysis of NP marker
gene expression after 14‐day culture. RhGDF6 delivered through MP release significantly upregulated expression of NP‐marker genes in culture.
Expression was normalised to housekeeping genes (GAPDH and MRPL19) and unstimulated negative control samples. In exogenous rhGDF6
supplemented groups, 100 ng ml−1 rhGDF6 was added to media at each media change. Data represents means ± scanning electron microscope
(n = 3; * p < .05 rhGDF6‐MP vs. rhGDF6; Δ p < .05 rhGDF6‐MP vs. Control MP; Ψ p < .05 rhGDF6‐MP vs. Negative Control; £ p < .05 rhGDF6 vs.
Control MP; # p < .05 rhGDF6 vs. Negative Control)
8 HODGKINSON ET AL.3.4 | RhGDF6 released from MPs increases sGAG
production by ASCs
After observing significant increases in NP‐marker gene expression in
ASCs with rhGDF6‐MP stimulation, the effect of stimulation on sGAG
and aggrecan synthesis and deposition by cells after 14 days in colla-
gen gel cultures were assessed through Safranin‐O/Fast GreenFIGURE 4 Histological and immunohistochemical staining of gel culture
after 14 days culture showing sGAG production. Greater density and distr
differentiation factor 6 (rhGDF6)–microparticle (MP) gels in comparison wit
showed corresponding levels of aggrecan in test groups, with rhGDF6‐MP
gel. Representative images, scale bars = 300 μm [Colour figure can be viewstaining and aggrecan IHC, respectively (Figure 4). Through Safranin‐
O staining, rhGDF6‐MP stimulation was shown to induce greatest
sGAG staining (red) in comparison with other test groups. Analysis of
gels in which rhGDF6 was delivered as a media supplement showed
sGAG staining though less extensive than rhGDF6‐MP gels and
restricted to pericellular areas. In control‐MP and negative control
groups, limited sGAG staining was observed with larger amounts ofs after 14 days. Safranin O/Fast Green staining of gel cross‐sections
ibution of sGAG staining (red) is seen in recombinant human growth
h control and rhGDF6 groups. Aggrecan immunohistochemical analysis
gels demonstrating aggrecan production and distribution through the
ed at wileyonlinelibrary.com]
HODGKINSON ET AL. 9Fast Green staining of collagenous matrix. These results were mirrored
in analysis of aggrecan‐specific IHC of gels where rhGDF6‐MP–
containing groups showed significantly increased aggrecan staining in
comparison with negative control and control‐MP groups. RhGDF6
groups also showed increased aggrecan staining to a similar extent
to MP‐delivered rhGDF6.3.5 | RhGDF6‐MPs maintains effective NP
differentiation of ASCs in hypoxic environments
The environment of the degenerative IVD is hypoxic, and any success-
ful regenerative therapy must function in this environment. Therefore,
the effectiveness of rhGD6‐MP to induce NP gene expression in ASCs
in hypoxic culture conditions was investigated and compared with
normoxic culture and control MP (Figure 5a). Under normoxic condi-
tions, the induction of NP gene expression by rhGDF6‐MP stimulation
was consistent with previous experiments (Clarke et al., 2014). In hyp-
oxic conditions, compared with hypoxic and normoxic culture with
control‐MPs, rhGDF6‐MPs significantly increased the expression of
SOX9 (p = 0.0002; p = .0003), COL2A (p = .012; p = .0027), ACAN
(p = .0006; p = .0003), FOXF1 (p < 0.0001; p < .0001), and KRT18
(p = .0004; p = .0004). Hypoxic conditions did result in differences in
expression in rhGDF6‐MP groups. Statistically significant increases in
FOXF1 expression (×4.5 vs. ×2.2; p < .0001) were observed with hyp-
oxic conditions but of note statistically significant decreases were
observed in KRT19 (×4.3 vs. ×1.2; p = .0005) and ACAN (×18.6 vs.
/×5.9; p = .009), though the latter remained significantly upregulated
vs. control conditions.
Secretion of the important NP ECM molecule aggrecan by ASCs
after 14 days culture was assessed using IHC (Figure 5b). Consistent
with previous results, culture with rhGDF6‐MP in normoxic conditions
produced an aggrecan‐rich ECM, with substantial increases in
aggrecan synthesis also demonstrated in rhGDF6‐MP samples under
hypoxic conditions.4 | DISCUSSION
Due to its anatomical location and the characteristics of the pathologi-
cal progression of IVD degeneration, it is an ideal target for combined
small molecule‐cell therapeutic regenerative medicine strategies. As
proven in other in vivo studies utilising small molecule bioactive factors
problems exist in delivered molecule half‐life, need for significantly
supraphysiological doses, off‐target effects, and the need for repeated
delivery, with the latter particularly problematic as needle puncture of
the AF induces IVD degeneration (Han et al., 2008; Zhang et al.,
2009). Therefore, the controlled release of growth factors from protec-
tive nano‐ and micro‐scale carriers offers an attractive alternative.
Here, we investigated the potential of polymer MPs to deliver
rhGDF6 in a 3D hydrogel culture model to induce NP differentiation
(defined by NP marker gene expression) in ASCs. Protein release data
and GDF6 ELISA assays demonstrated that, as designed, encapsulated
rhGDF6 delivery was controlled over 14 days under cultureconditions. The MP system utilised here was designed to deliver
rhGDF6 over a 14‐day period as previous work had found this to be
sufficient to induce NP gene expression in ASCs (Clarke et al., 2014).
However, the MPs have been developed to allow easy manipulation
of both rhGDF6 “payload” and delivery time through alteration of
polymer composition, which is likely to be useful in vivo for the tuning
of treatments to patient needs. Furthermore, the MPs used here
(mean diameter 14–19 μm) do not interfere with hydrogel gelation,
even at concentrations 20 times those required to deliver optimised
concentrations of rhGDF6 for in vitro differentiation. This gives signif-
icant flexibility for alteration of dose and MP density if in vivo optimi-
sation is required. Adding this to their ease of incorporation into pre‐
gel solutions prior to gelation makes this method of rhGDF6 delivery
attractive as an injectable therapy for IVD degeneration.
In this system, the released rhGDF6 remained active andwas able to
activate smad1/5/8 signalling and significantly increased the expression
of NP marker genes over 14‐days culture. The induction of NP‐marker
gene expression in ASCs through rhGDF6 stimulation here corresponds
with previous work (Clarke et al., 2014). Crucially, MP delivery of
rhGDF6 significantly increased NP marker gene expression in compari-
son with rhGDF6 delivered as a media supplement in the majority of
cases. This is likely due to MP delivery increasing rhGDF6 availability
to cells in comparison with diffusion into gels from media. This finding
is highly pertinent to IVD regeneration as the disc is an avascular tissue
that relies solely on diffusion for nutrient and growth factor delivery and
the fibrotic changes associated with degeneration limit such diffusion
through the tissue. It also demonstrates that rhGDF6 encapsulation in
MPs retained its bioactivity over the 14‐day time course, highlighting
that theseMPs have potential for delivery of rhGDF6within the degen-
erative IVD over extended time periods without loss of bioactivity.
The degenerative NP is a hypoxic environment, therefore we tested
the performance of MP delivered rhGDF6 in a 3D hypoxic culture
model. In this system, culture in hypoxia did not significantly affect
the expression of the majority of NP marker genes tested. Crucially,
three major indicators of NP differentiation SOX9, COL2A1, and ACAN
all remained statistically significantly upregulated versus unstimulated
control cultures. Expression of the novel NP target KRT19was reduced
in hypoxic conditions compared with normoxic rhGDF6‐MP popula-
tions, though Keratin 18 was elevated comparably in both hypoxia
and normoxia. Future research into the details of rhGDF6 signalling
could be critical for fully understanding the reasons behind this effect.
Aggrecan immunostaining of normoxic and hypoxic gels demonstrated
that rhGDF6‐mediated stimulation of proteoglycan production is main-
tained even in conditions mimicking the degenerative NP suggesting
that hypoxia would not be detrimental to GDF6‐induced differentiation
of ASCs to NP cells and appropriate NP‐like ECM secretion.
For future translation, it would be essential to investigate
the influence of total GDF6 dose, release rate, and release duration
on ASC differentiation and tissue regeneration in vivo. It will also
be important to assess other microenvironmental factors, including
pH which is known to decrease with degeneration and has been shown
to influence both native NP cell phenotype (Gilbert, Hodson, Baird,
Richardson, & Hoyland, 2016) and the regenerative potential of
FIGURE 5 Effect of hypoxic culture conditions on effectiveness of recombinant human growth differentiation factor 6 (rhGDF6)–microparticle
(MP) to induce adipose stem cell differentiation and aggrecan synthesis. (a) Quantitative polymerase chain reaction analysis of nucleus pulposus
(NP)–marker gene expression after 14 days culture in normoxic (20% [v/v] O2) or hypoxic (5% (v/v) O2) conditions in the presence of rhGDF6‐MPs
or control‐MPs. Expression was normalised to housekeeping genes (GAPDH and MRPL19) and unstimulated control samples. Data represents
means ± scanning electron microscope (n = 3; * p < .05 rhGDF6‐MP Normoxia vs. rhGDF6‐MP Hypoxia; Δ p < .05 rhGDF6‐MP Normoxia vs.
Control MP Hypoxia; Ψ p < 0.05 rhGDF6‐MP Normoxia vs. Control MP Normoxia; £ p < .05 rhGDF6‐MP Hypoxia vs. Control MP Hypoxia; #
p < .05 rhGDF6‐MP Hypoxia vs. Control MP Normoxia). RhGDF6‐MPs were able to upregulate NP‐marker gene expression in hypoxic culture
conditions, though in the majority of cases, no additive effect was observed through hypoxic culture. (b) Aggrecan immunohistochemical analysis
staining of gel cultures after 14 days demonstrating increased deposition in normoxic versis hypoxic cultures, with enhanced staining in rhGDF6‐
MP cultures compared with control cultures [Colour figure can be viewed at wileyonlinelibrary.com]
10 HODGKINSON ET AL.implanted MSCs/ASCs (Naqvi & Buckley, 2016). Although degradation
of PLGA/PLA‐containing MPs results in acidic by‐products, the rela-
tively slow degradation rate of our MP system, combined with the abil-
ity to minimise MP density through optimisation of GDF6 loading and
release rate, will enable clearance from the tissue through normal met-
abolic processes and reduce the risk of by‐product accumulation and
associated reduction in pH.5 | CONCLUSION
In conclusion, this work has demonstrated the controlled delivery of
rhGDF6 to ASCs in a 3D in vitro hydrogel model through MP encap-
sulation. The rhGDF6 delivered in this manner induced ASCs differen-
tiation to NP cells and production of an aggrecan‐rich NP‐like ECM
over a 14‐day period to levels at least equivalent to that achieved by
HODGKINSON ET AL. 11exogenous addition of GDF6. Encapsulation in MPs retained rhGDF6
bioactivity over the 14‐day time‐course, and this bioactivity remained
effective even under hypoxic culture conditions that mimic the degen-
erative NP. As such, this data serves as important proof of principle
study that the MP delivery of rhGDF6 described in this manuscript
offers a versatile and attractive method for future in vivo treatment
of IVD degeneration and requires further investigation in vivo in
appropriate degenerative IVD animal models.
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